HSP induction mediates selective clearance of tau phosphorylated at proline-directed Ser/Thr sites but not KXGS (MARK) sites

被引:132
作者
Dickey, Chad A.
Dunmore, Judith
Lu, Bingwei
Wang, Ji-Wu
Lee, Wing C.
Kamal, Adeela
Burrows, Francis
Eckman, Christopher
Hutton, Michael
Petrucelli, Leonard
机构
[1] Mayo Clin Jacksonville, Coll Med, Jacksonville, FL 32224 USA
[2] Stanford Univ, Stanford, CA 94305 USA
[3] Conforma Therapeut Corp, San Diego, CA USA
关键词
neurofibrillary tangles; Alzheimer's disease; proteasome;
D O I
10.1096/fj.05-5343fje
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Neurofibrillary tangles (NFTs) are a characteristic neuropathological feature of Alzheimer's disease (AD), and molecular chaperones appear to be involved in the removal of disease-associated hyperphosphorylated tau, a primary component of NFTs. Here, novel HSP90 inhibitors were used to examine the impact of chaperone elevation on clearance of different tau species in transfected cells using a unique quantitative assay. The HSP90 inhibitors reduced levels of tau phosphorylated at proline-directed Ser/Thr sites (pS202/T205, pS396/S404) and conformationally altered ( MC-1) tau species, an epitope that is immeasurable by standard Western blot techniques. The selective clearance of these phospho-tau species and MC-1 tau was mediated via the proteasome, while lysosomal-mediated tau degradation seems to lack specificity for certain tau species, suggesting a more general role in total tau removal. Interestingly, tau phosphorylated at S262/S356 within the tau microtubule binding domain was minimally affected by chaperone induction. Overall, our data show that chaperone induction results in the selective clearance of specific phospho-tau and conformationally altered tau species mediated by the proteasome; however, the apparent stability of pS262/S356 tau may also explain why MARK is able to regulate normal tau function yet still be linked to the initiation of pathogenic tau hyperphosphorylation in AD.
引用
收藏
页码:753 / +
页数:18
相关论文
共 22 条
[1]  
Bagatell R, 2004, MOL CANCER THER, V3, P1021
[2]   Protein kinase MARK/PAR-1 is required for neurite outgrowth and establishment of neuronal polarity [J].
Biernat, J ;
Wu, YZ ;
Timm, T ;
Zheng-Fischhöfer, QY ;
Mandelkow, E ;
Meijer, L ;
Mandelkow, EM .
MOLECULAR BIOLOGY OF THE CELL, 2002, 13 (11) :4013-4028
[3]   CHIP activates HSF1 and confers protection against apoptosis and cellular stress [J].
Dai, Q ;
Zhang, CL ;
Wu, YX ;
McDonough, H ;
Whaley, RA ;
Godfrey, V ;
Li, HH ;
Madamanchi, N ;
Xu, W ;
Neckers, L ;
Cyr, D ;
Patterson, C .
EMBO JOURNAL, 2003, 22 (20) :5446-5458
[4]  
Dickey Chad A., 2005, Current Alzheimer Research, V2, P231, DOI 10.2174/1567205053585927
[5]   MARK, a novel family of protein kinases that phosphorylate microtubule-associated proteins and trigger microtubule disruption [J].
Drewes, G ;
Ebneth, A ;
Preuss, U ;
Mandelkow, EM ;
Mandelkow, E .
CELL, 1997, 89 (02) :297-308
[6]   Segregation of a missense mutation in the microtubule-associated protein tau gene with familial frontotemporal dementia and parkinsonism [J].
Dumanchin, C ;
Camuzat, A ;
Campion, D ;
Verpillat, P ;
Hannequin, D ;
Dubois, B ;
Saugier-Veber, P ;
Martin, C ;
Penet, C ;
Charbonnier, F ;
Agid, Y ;
Frebourg, T ;
Brice, A .
HUMAN MOLECULAR GENETICS, 1998, 7 (11) :1825-1829
[7]   Association of missense and 5′-splice-site mutations in tau with the inherited dementia FTDP-17 [J].
Hutton, M ;
Lendon, CL ;
Rizzu, P ;
Baker, M ;
Froelich, S ;
Houlden, H ;
Pickering-Brown, S ;
Chakraverty, S ;
Isaacs, A ;
Grover, A ;
Hackett, J ;
Adamson, J ;
Lincoln, S ;
Dickson, D ;
Davies, P ;
Petersen, RC ;
Stevens, M ;
de Graaff, E ;
Wauters, E ;
van Baren, J ;
Hillebrand, M ;
Joosse, M ;
Kwon, JM ;
Nowotny, P ;
Che, LK ;
Norton, J ;
Morris, JC ;
Reed, LA ;
Trojanowski, J ;
Basun, H ;
Lannfelt, L ;
Neystat, M ;
Fahn, S ;
Dark, F ;
Tannenberg, T ;
Dodd, PR ;
Hayward, N ;
Kwok, JBJ ;
Schofield, PR ;
Andreadis, A ;
Snowden, J ;
Craufurd, D ;
Neary, D ;
Owen, F ;
Oostra, BA ;
Hardy, J ;
Goate, A ;
van Swieten, J ;
Mann, D ;
Lynch, T .
NATURE, 1998, 393 (6686) :702-705
[8]   ALZ-50 ANTIBODY RECOGNIZES ALZHEIMER-RELATED NEURONAL CHANGES [J].
HYMAN, BT ;
VANHOESEN, GW ;
WOLOZIN, BL ;
DAVIES, P ;
KROMER, LJ ;
DAMASIO, AR .
ANNALS OF NEUROLOGY, 1988, 23 (04) :371-379
[9]  
McDonough H, 2003, CELL STRESS CHAPERON, V8, P303, DOI 10.1379/1466-1268(2003)008<0303:CALBTC>2.0.CO
[10]  
2